Company: HURA
Filing Date: 2025-06-06
Form Type: 425
Source: 0001193125-25-137145
Chunk: 2

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-06-06
Form: 425
Chunk 2
---
”) have been satisfied (other than conditions that cannot be satisfied until on or immediately 
 before the closing of the Kineta Merger) and that the Company is prepared to close the Kineta Merger.                                                                                                                                    |

In addition to the approximately $8.9 million that will be purchased in four equal tranches pursuant to the foregoing milestones, the remaining $3.7 million in the Offering is required to be purchased and funded by December 31, 2025 by certain Purchasers who agreed to invest an aggregate of $4.0 million or more in the Offering and who elected to defer the purchase of a portion of such Purchaser’s Common Stock and Warrants until such time. The Company received aggregate gross proceeds from the Initial Closing of approximately $2.23 million, before deducting fees to the placement agents and other estimated offering expenses payable by the Company. The Company will receive an additional $10.38 million in gross proceeds from the additional closings above, provided that the conditions to funding are satisfied. The Company currently plans to use the net proceeds from the Offering for cash requirements for the closing of the proposed merger with Kineta, Inc., to fund the initiation of the Phase 3 Trial for IFx-2.0,to fund the advancement of KVA12123 to a Phase 2 trial and for other working capital needs. The Warrants have an exercise price per share equal to $3.3125 and will expire on the fifth (5th) anniversary of the later of (i) December 3, 2025 and (ii) the date of the implementation of the Authorized Share Increase Proposal in the Company’s Form S-4Registration Statement relating to the Kineta Merger. The exercise price of the Warrants is subject to proportional adjustment for stock splits, reverse stock splits, and similar transactions. The Shares, Warrants and the shares of Common Stock issuable upon exercise of the Warrants were issued in a private placement and have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), and are instead being offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and/or Rule 506(b) promulgated thereunder. The Company has agreed to file a registration statement to register the resale of the Shares and shares of Common Stock underlying the Warrants no later than 60 calendar days following the date of the Initial Closing and to use reasonable efforts to cause such registration statement to become effective within 120 calendar days following the